wellrank.ai
Onduo logo

Onduo

First cited by AI Jun 12, 2026
onduo.com

Surfaced organically in AI answers about ozempic. Not yet profiled.

Onduo is losing the AEO war.

Not cited in a single tracked AI answer since Jun 13, 2026, down from a peak of 8% visibility in ozempic on Jun 13, 2026. This page and its history stay public, and recovery shows here the day it happens.

AI Visibility

Visibility trend

Ozempic, daily share of AI answers mentioning Onduo, through Jun 14, 2026.

0.0%

Last cited Jun 13, 2026 · peak 8% on Jun 13

By engine

Where Onduo is strong, and where it is invisible.

  • No engine data yet.

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 0 positive mentions
  • 2 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Onduo

ChatGPTJun 13, 2026, 11:12 UTC
What are the best alternatives if I cannot get Ozempic, and who prescribes them online?

Short answer: If you can’t get Ozempic (semaglutide), the main alternatives are other GLP‑1 (and new dual‑agonist) drugs used for diabetes and/or weight loss, plus older diabetes classes (metformin, SGLT2s, DPP‑4s, insulin). All require a prescription and medical evaluation. Key medication alternatives (brand names and why you’d consider them) Wegovy (semaglutide 2.4 mg) — same active drug as Ozempic but FDA‑approved specifically for chronic weight management (different dosing). Good alternative for weight loss if available/covered. Rybelsus (oral semaglutide) — oral form of semaglutide for type 2 diabetes if you want to avoid injections (lower doses than Wegovy). Mounjaro (tirzepatide) — a GIP/GLP‑1 dual agonist for type 2 diabetes that has shown larger weight loss in trials; available as a diabetes drug. Zepbound (tirzepatide) is approved for weight management. Trulicity (dulaglutide) — weekly GLP‑1 injection for type 2 diabetes; well‑established alternative when semaglutide isn’t an option. Victoza (liraglutide) and Saxenda (liraglutide) — Victoza for diabetes, Saxenda for weight loss (same active drug, different dose/indication). Bydureon/Byetta (exenatide) — older GLP‑1 options (weekly and twice‑daily formulations). If GLP‑1s aren’t appropriate: metformin, SGLT2 inhibitors (Jardiance/empagliflozin, Farxiga/dapagliflozin), DPP‑4 inhibitors (Januvia/sitagliptin), or insulin — these manage blood sugar but are not as effective for weight loss. Who prescribes these online (telemedicine services) Onduo — digital diabetes care platform that connects you with clinicians specializing in diabetes and can prescribe diabetes medications. PlushCare — primary‑care telemedicine that manages chronic conditions (diabetes, weight) and can prescribe GLP‑1s and other diabetes meds when appropriate. SteadyMD — long‑term telehealth primary care; good if you want ongoing management and prescriptions for chronic meds. Ro (including Ro’s weight‑loss program) — offers telemedicine weight‑loss programs and has prescribed GLP‑1s in their programs. Hims & Hers (weight‑loss services) — offers telemedicine evaluation and GLP‑1 prescribing through their weight‑loss service in some states. GoodRx Care — provides telehealth visits and may prescribe some diabetes/weight‑loss medications; useful for comparing prices and coupons. Your insurer’s telemedicine or local tele‑endocrinology services — many insurers or health systems offer virtual visits with prescribers who can manage diabetes meds. Notes and cautions All these drugs require a medical assessment (history, current meds, possible labs like HbA1c, kidney function, pregnancy testing). Some online clinics require or help arrange labs before prescribing. Prior authorization, insurance coverage, and supply shortages are common; online clinics can sometimes help with prior auth or patient assistance programs but availability varies. GLP‑1s and tirzepatide have side effects (nausea, pancreatitis risk, gallbladder issues, rare thyroid C‑cell tumor concerns in rodents) and aren’t safe in pregnancy — discuss risks with a clinician. If your goal is weight loss, note that some diabetes doses are “off‑label” for weight; Wegovy and Zepbound are the FDA‑approved weight drugs. If you want, tell me: whether you need help finding telemedicine providers that operate in your state, whether your priority is diabetes control or weight loss, and whether you have insurance (so I can point to options that are more likely to work for you).

Mentioned in position 1 of 6

Read full answer with sources →
ChatGPTJun 12, 2026, 11:52 UTC
What telehealth companies prescribe Ozempic?

Short answer: Many mainstream telehealth and virtual primary‑care companies will evaluate patients for semaglutide (the drug class that includes Ozempic) and — if clinically appropriate and allowed in your state — can prescribe it. Which companies actually prescribe Ozempic specifically (vs. other semaglutide brands like Wegovy or alternative GLP‑1s/tirzepatide) varies by provider, state rules, and your medical history. Telehealth companies that commonly evaluate and may prescribe Ozempic/other GLP‑1s PlushCare — virtual primary care and urgent visits; board‑certified clinicians who manage diabetes and weight‑loss meds. Ro (Roman) — offers dedicated weight‑loss and metabolic care programs and will prescribe GLP‑1s when appropriate. Hims & Hers — has a weight‑loss/GLP‑1 program and telemedicine visits for prescription management. Teladoc — large telehealth network with primary‑care and specialty clinicians who treat chronic conditions including diabetes. Amwell — telehealth platform connecting you to primary‑care and endocrine clinicians who can prescribe GLP‑1s after evaluation. One Medical — membership primary care (virtual + in‑person) that manages chronic meds and can prescribe GLP‑1s. Onduo — virtual diabetes care program (Google/Verily/Sanofi partnership) focused on diabetes management and access to diabetes meds. Lemonaid Health — online clinic that prescribes various chronic meds and operates in many states; may offer GLP‑1s in eligible patients. GoodRx Care (formerly HeyDoctor) — online visit service that sometimes prescribes GLP‑1s and can help with pricing/discounts. Important notes before you try: Ozempic is FDA‑approved for type 2 diabetes; Wegovy (also semaglutide) is the brand approved for chronic weight management. Many clinicians will choose the appropriate brand/dose based on diagnosis and insurance. Telehealth providers will require a medical evaluation, review of your history and possibly labs (A1c, kidney function), and may decline to prescribe if it’s unsafe or off‑label for your situation. State laws, company policies, and supply shortages affect availability. Prices/insurance coverage vary widely; some programs help with manufacturer savings programs but may not cover the drug. Beware of services that advertise prescription shipments without a live clinical evaluation — that’s unsafe and often illegal. If you want, tell me your state and whether you have insurance — I can check which of these services operate there, or help you compare out‑of‑pocket costs and entry steps.

Mentioned in position 7 of 12

Read full answer with sources →

Public AI visibility history

Daily rank of Onduo on our buyer intent questions, per category. A dash means the engines did not cite Onduo at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13Jun 14
Ozempic#74#43

TL;DR

Onduo is a virtual care platform focused on chronic condition management, particularly type 2 diabetes, developed as a joint venture between Sanofi and Verily (Alphabet's life sciences arm). It offers a technology-guided program combining connected devices, coaching, and clinical care. In WellRank's latest index, Onduo ranks 15th in AI-generated answers about Ozempic with 8% visibility, and the two mentions captured in the corpus are both neutral in tone, suggesting it surfaces as a factual reference rather than a recommended destination.

Company Overview

Onduo was established as a joint venture between Sanofi and Verily to deliver virtual, technology-enabled management for chronic diseases, with a primary focus on type 2 diabetes. The business model is oriented toward employer and health plan partnerships rather than direct-to-consumer retail, meaning individuals typically access Onduo through their employer benefits program. Its headquarters and exact founding year are not consistently reported in public sources.

Product Features

  • Virtual diabetes management program combining continuous glucose monitoring with coaching
  • Remote clinical care including access to physicians and certified diabetes educators
  • Personalized lifestyle and medication guidance delivered through a mobile app
  • Integration with connected health devices to track glucose and activity data
  • Population health analytics tools for employer and health plan partners

Target Market

Onduo primarily serves adults living with type 2 diabetes, and has expanded into related cardiometabolic conditions. Its go-to-market approach targets US-based employers and health insurers who offer the program as a covered benefit to their members or employees.

Buyer Personas

  • A mid-career employee with a recent type 2 diabetes diagnosis whose employer offers Onduo as a no-cost benefit through their health plan.
  • An HR or benefits manager at a self-insured company seeking data-backed chronic disease management programs to reduce long-term healthcare costs.
  • A health plan medical director evaluating digital therapeutics partners to improve outcomes and adherence among a diabetic member population.
  • An adult managing both type 2 diabetes and weight concerns who wants coordinated virtual clinical care rather than fragmented specialist visits.

Funding & Performance

Onduo was founded as a joint venture backed by Sanofi and Verily, both large, well-resourced parent organizations, so traditional venture funding rounds are not applicable. Specific investment amounts committed by either parent company and any standalone valuation are not publicly disclosed.

Recent Developments

Onduo has been publicly associated with expanding its virtual care scope beyond diabetes to broader cardiometabolic and hypertension management, reflecting a wider industry trend toward whole-person chronic care. Its relationship with Sanofi has drawn attention in the context of GLP-1 medications, which likely explains its organic appearance in AI answers about Ozempic tracked by WellRank. The specifics of any recent product launches or partnership announcements beyond these general directions are not consistently confirmed in public reporting.

Competitive Landscape

WellRank's co-mention data shows Onduo appearing alongside Ro, Hims & Hers, PlushCare, GoodRx Care, Teladoc, SteadyMD, and its own parent Verily in AI-generated responses. This places it in a competitive set that spans direct-to-consumer telehealth prescribers, general virtual primary care platforms, and employer-focused digital health companies. Onduo's employer-and-payer distribution model differentiates it structurally from consumer-facing peers like Ro and Hims & Hers, though all compete for mindshare in AI answers about chronic disease and weight management treatments.

Mentioned alongside

Brands AI engines recommend in the same breath. Your real competitive set.

User Sentiment

The two Onduo mentions captured in WellRank's corpus are both neutral, with no positive or cautious signals recorded, suggesting AI engines treat it as an informational reference point rather than a strongly recommended service. Public consumer reviews are relatively sparse compared to direct-to-consumer telehealth brands, consistent with its employer-mediated distribution model where beneficiaries may not independently seek it out. This limited sentiment signal also means the brand has meaningful room to build a more distinctive presence in AI-generated health answers.

Pricing

Because Onduo is distributed through employer and health plan partnerships, pricing is structured as a business-to-business arrangement and is not published for consumers. Individual end users typically access the program at no direct cost if their employer or insurer has contracted with Onduo; specific contract pricing for plan sponsors is not publicly disclosed.

Sources cited around Onduo

The sites engines cite in answers mentioning this brand. Win these, win the answer.

    Track Onduo weekly

    One email a week: rank moves, new competitors, and the answers that changed. No noise.

    Work at Onduo? Get your AI Visibility Audit.

    See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.